 |
|
Effect of Aspirin Use on Thiazolidinediones and Cardiovascular Events
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: Dr Lipscombe and colleagues1 conducted a retrospective study to explore the association between cardiovascular events and thiazolidinediones (TZDs) compared with other oral hypoglycemic agents. However, their study did not report on concomitant use of aspirin among patients on TZDs and oral hypoglycemics. There was no adjustment for aspirin use and dose of aspirin. Therefore, an apparent increase in the risk of adverse cardiovascular events from TZDs may have been observed because concomitant exposure to a confounder that is protective for the adverse outcome (aspirin and cardiovascular events) was not accounted for. This is particularly important since the PROactive Study, which indicated that pioglitazone reduced the composite of all-cause mortality, nonfatal myocardial infarction, and stroke in patients with type 2 diabetes mellitus, did report a similar frequency of aspirin use among patients treated with pioglitazone and placebo (75% vs 72%, respectively).2
Aspirin use may also be relevant to . . . [Full Text of this Article]
Panagiotis A. Konstantinopoulos, MD, PhD
pkonstan@bidmc.harvard.edu
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Michalis V. Karamouzis, MD, PhD
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania
Athanasios G. Papavassiliou, MD, PhD
University of Athens School of Medicine
Athens, Greece
RELATED ARTICLE
Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes
Lorraine L. Lipscombe, Tara Gomes, Linda E. Lévesque, Janet E. Hux, David N. Juurlink, and David A. Alter
JAMA. 2007;298(22):2634-2643.
ABSTRACT
| FULL TEXT
RELATED LETTER
Effect of Aspirin Use on Thiazolidinediones and Cardiovascular Events—Reply
Lorraine L. Lipscombe and David A. Alter
JAMA. 2008;299(13):1539-1540.
EXTRACT
| FULL TEXT
|
